Clinical Analysis Of The Relationship Between Type2Diabetes Mellitus And Occurrence Rate And Prognosis Of Ovarian Cancer

Background and ObjectivesWith the improvement of people’s living standard and change of the life styles, the incidence of diabetes mellitus and malignant tumors increases. Both are chronic diseases including multiple factors, mechanisms and involving multi-system. Yet people find some similarities during the study of them. A number of studies both at home and abroad have shown that the susceptibility of malignant tumor in patients with Type2diabetes mellitus increases, we have so far confirmed that Type2diabetes mellitus is the risk factor of the pathogenesis of colorectal cancer, pancreatic cancer and the liver cancer and influences the patients’ prognosis. Some reports abroad have shown that Type2diabetes mellitus may have involvement with gynecological malignant tumors. However, there are few researches about the relationship between Type2diabetes mellitus and the occurrence and development of ovarian cancer.This paper retrospectively analyzed130cases of ovarian cancer with or without diabetes mellitus in order to discuss the relationship between diabetes mellitus and ovarian cancer on the incidence of ovarian cancer, surgical-pathologic stage, pathological types and the prognosis.Objects and Methods130cases of ovarian cancer with or without diabetes mellitus who were diagnosed and treated with standard measures in our hospital from January1,2007to January1,2010were analyzed restrospectively, Among which,24cases were with diabetes mellitus, aged from41to75years and the average age was (57.8±10.4) years; the rest106patients were aged from33to72years and the average age was (53.8±11.2) years, without a statistical difference (.P>0.05). We got access to those records data and used the telephone and outpatient medical records to do the follow-up,observe and analyze seperately both surgical-pathologic stage, pathological type and the prognosis, and compared their differences.Type2Diabetes mellitus was diagnosed according to the new guideline published by the American Diabetes Association; All the patients were treated by the latest NCCN guideline to do overall staging surgery or optimal cytoreductive surgery, with residual cancer less than1cm and supplementary Paclitaxel&Carboplatin solution6courses of chemotherapy after surgery, Then we confirmed ovarian cancer stage, grading, and histo-pathological types according to2009FIGO guideline.Survival time is defined as the time from diagnosis day to the follow-up deadline: January1,2012or until death. SPSS17.0is used to analyze the data by using T Test and χ2Test, a=0.05is considered to be as the detection standard. Kaplan-Meier survival curves is used to calculate3year and5year survival rate.Results124patients were with diabetes mellitus among130ovarian cancer patients,the prevalence was18.5%;2Ovarian cancer patients with and without diabetes mellitus treated with initial stage Ⅲ～Ⅳ patients were83.3%、61.3%, with a statistically significant difference (χ2=4.19, P=0.04);3There was no big difference about pathological type (χ2=0.12, P=0.94)4Patients combined with type2diabetes’ median survival time (27months) the3years survival rate (31.6%) and the5years survival rate(13.5%) were significantly lower than those without diabetes mellitus, with median survival time (44months)、the3years survival rate (55.1%) and the5years survival rate(32.0%)(χ2=11.71,P=0.01).Conclusions1Type2diabetes mellitus increases the occurrence rate of ovarian cancer;2The ovarian cancer patients with diabetes mellitus are often diagnosed at a more advanced tumor stage and have a worse prognosis.